Literature DB >> 11453953

Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease.

M Losa1, P Mortini, S Dylgjeri, R Barzaghi, A Franzin, C Mandelli, M Giovanelli.   

Abstract

OBJECTIVE: The desmopressin test has been proposed as a useful tool for the differential diagnosis of Cushing's disease. The aim of our study was to investigate, in a large series of patients with Cushing's disease, the incidence of a positive ACTH and cortisol response to desmopressin. Moreover, we repeated the test soon after surgery to verify its usefulness in the assessment of early and late surgical results. PATIENTS AND METHODS: One hundred and seven consecutive patients with Cushing's disease, 89 female and 18 male patients, with a mean age of 37.2 +/- 1.3 years, were studied. All patients, except three, repeated the test 5-6 days after surgery. Desmopressin (10 microg) was injected i.v. and blood samples were drawn 15, 30, 45 and 60 minutes thereafter. Plasma ACTH and serum cortisol were measured in duplicate by commercially available immunoassays. A positive response to desmopressin was considered to be a plasma ACTH and serum cortisol increment of at least 30% and 20% above baseline, respectively.
RESULTS: Mean basal plasma ACTH level was 17.3 +/- 1.7 pmol/l and rose to a peak level of 42.7 +/- 4.9 pmol/l at 15 minutes Mean basal serum cortisol level was 574 +/- 19 nmol/l and rose to a peak level of 814 +/- 28 nmol/l at 45 minutes. ACTH and cortisol incremental changes were inversely correlated with their respective basal levels. Ninety patients (84.1%) had an ACTH and 84 patients (78.5%) had a cortisol response to desmopressin. Several clinical and demographic characteristics were not significantly different among desmopressin responders and non responders, except that basal ACTH and cortisol levels were significantly higher in desmopressin non responders (27.2 +/- 8.3 pmol/l, 781 +/- 86 nmol/l) than in desmopressin responders (15.4 +/- 1.2 pmol/l, 535 +/- 14 nmol/l). Disappearance of the ACTH and cortisol response to desmopressin after surgery occurred in 50 of 87 (57%) ACTH responders and in 57 of 81 (70.4%) cortisol responders, respectively. However, concordance between the desmopressin test and surgical outcome was not complete. Indeed, 18 patients considered in remission still showed an ACTH increase after desmopressin and, on the contrary, four patients with disappearance of the ACTH response had persistence of hypercortisolism. During follow-up monitoring, three patients, who had persistence of the ACTH response to desmopressin, relapsed 24, 38 and 54 months after surgery.
CONCLUSIONS: Desmopressin administration elicits a significant rise in ACTH and cortisol levels in the majority but not all patients with Cushing's disease. There is a good, but not complete, concordance between the response to the desmopressin test and the surgical outcome. Our preliminary data show that persistence of the ACTH response to desmopressin in the early postoperative period might be associated with a higher risk of late relapse.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453953     DOI: 10.1046/j.1365-2265.2001.01324.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  13 in total

1.  Recurrence of Cushing's disease preceded by the reappearance of ACTH and cortisol responses to desmopressin test.

Authors:  Chiara Dall'Asta; Laura Barbetta; Luigi Bonavina; Paolo Beck-Peccoz; Bruno Ambrosi
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Safety of transsphenoidal microsurgical approach in patients with an ACTH-secreting pituitary adenoma.

Authors:  Carmine Antonio Donofrio; Marco Losa; Marco Gemma; Lodoviga Giudice; Lina Raffaella Barzaghi; Pietro Mortini
Journal:  Endocrine       Date:  2016-12-22       Impact factor: 3.633

4.  Clinical characteristics and surgical outcome in USP8-mutated human adrenocorticotropic hormone-secreting pituitary adenomas.

Authors:  Marco Losa; Pietro Mortini; Angela Pagnano; Mario Detomas; Maria Francesca Cassarino; Francesca Pecori Giraldi
Journal:  Endocrine       Date:  2018-10-12       Impact factor: 3.633

Review 5.  Peri-operative management of Cushing's disease.

Authors:  Dima AbdelMannan; Warren R Selman; Baha M Arafah
Journal:  Rev Endocr Metab Disord       Date:  2010-06       Impact factor: 6.514

6.  The postoperative basal cortisol and CRH tests for prediction of long-term remission from Cushing's disease after transsphenoidal surgery.

Authors:  John R Lindsay; Edward H Oldfield; Constantine A Stratakis; Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2011-04-20       Impact factor: 5.958

7.  Cushing's Disease: The Relevance of a Combined Dexamethasone Desmopressin Test as a Component of Postoperative Hormonal Evaluation.

Authors:  Przemysław Witek; Grzegorz Zieliński; Katarzyna Szamotulska
Journal:  Int J Endocrinol       Date:  2015-06-22       Impact factor: 3.257

Review 8.  Detection of recurrent Cushing's disease: proposal for standardized patient monitoring following transsphenoidal surgery.

Authors:  Alejandro Ayala; Alex J Manzano
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

9.  The prognostic value of perioperative profiles of ACTH and cortisol for recurrence after transsphenoidal hypophysectomy in dogs with corticotroph adenomas.

Authors:  S J van Rijn; J M Hanson; D Zierikzee; H S Kooistra; L C Penning; M A Tryfonidou; B P Meij
Journal:  J Vet Intern Med       Date:  2015-05-08       Impact factor: 3.333

10.  Duration of post-operative hypocortisolism predicts sustained remission after pituitary surgery for Cushing's disease.

Authors:  Prachi Bansal; Anurag Lila; Manjunath Goroshi; Swati Jadhav; Nilesh Lomte; Kunal Thakkar; Atul Goel; Abhidha Shah; Shilpa Sankhe; Naina Goel; Neelam Jaguste; Tushar Bandgar; Nalini Shah
Journal:  Endocr Connect       Date:  2017-09-14       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.